샘플 요청 목록

 카트 문의
시장보고서
상품코드
1536219

세계의 담관암 치료제 시장

Cholangiocarcinoma Therapeutics
발행일: | 리서치사: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 페이지 정보: 영문 182 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

담관암 치료제 세계 시장 규모는 2030년까지 9억 6,200만 달러에 달할 것으로 전망

2023년 8억 6,380만 달러로 추정되는 담관암 치료제 세계 시장은 2023년부터 2030년까지 연평균 1.6% 성장하여 2030년에는 9억 6,200만 달러에 달할 것으로 예상됩니다. 본 보고서에서 분석한 부문 중 하나인 표적 치료는 CAGR 2.0%를 기록하여 분석 기간이 끝날 때까지 5억 9,250만 달러에 도달할 것으로 예상됩니다. 화학 요법 분야의 성장률은 분석 기간 동안 CAGR 0.8%로 추정됩니다.

미국 시장 2억 2,710만 달러로 추정, 중국은 CAGR 1.3%로 성장할 것으로 예상

미국의 담관암 치료제 시장은 2023년 2억 2,710만 달러로 추정됩니다. 세계 2위의 경제 대국인 중국은 2030년까지 시장 규모가 1억 5,320만 달러에 달할 것으로 예상되며, 2023-2030년 분석 기간 동안 1.3%의 연평균 복합 성장률(CAGR)을 나타낼 것으로 예상됩니다. 다른 주목할 만한 지역 시장으로는 일본과 캐나다가 있으며, 분석 기간 동안 각각 1.2%와 1.3%의 연평균 복합 성장률(CAGR)을 나타낼 것으로 예상됩니다. 유럽에서는 독일이 약 0.5%의 연평균 복합 성장률(CAGR)로 성장할 것으로 예상됩니다.

세계 담관암 치료제 시장 - 주요 동향 및 촉진요인 요약

담관암은 담관암이라고도 불리는 담관암은 드물지만 담관에 발생하는 침습성 암입니다. 초기에는 무증상인 경우가 많아 진행된 상태에서 진단되는 경우가 많아 치료가 복잡해지고 예후가 나빠지는 경우가 많습니다. 담관암의 표준 치료법으로는 수술, 항암화학요법, 방사선치료가 있습니다. 수술, 특히 절제술이 가장 좋은 치료 가능성을 제공하지만, 질병이 느리게 진행되기 때문에 수술이 가능한 환자는 극소수에 불과합니다. 절제 불가능한 환자나 전이성 환자의 화학요법으로는 젬시타빈과 시스플라틴의 병용요법이 일반적으로 사용되지만, 이러한 치료는 완치보다는 생존기간 연장이 주된 목적입니다. 최근 표적치료제와 면역치료제가 등장하면서 새로운 치료의 길을 열어 진행성 담관암 환자들에게 희망을 주고 있습니다.

분자생물학과 유전학의 발전은 담관암 치료제의 상황을 크게 변화시켰고, 표적치료제 개발로 이어졌습니다. 이러한 치료법은 암의 성장을 가속하는 특정 유전자 돌연변이 또는 변화를 공격하도록 설계되었습니다. 예를 들어, FGFR2(섬유아세포 성장인자 수용체 2) 융합과 IDH1(이소구연산 탈수소효소 1) 돌연변이는 일부 담관암 환자에서 발견되어 새로운 약물의 표적이 되고 있으며, FGFR 억제제인 페미가티닙과 인플리그라티닙은 모두 임상시험에서 효능을 입증하여 FGFR 2 융합 환자들에게 새로운 치료 옵션을 제공합니다. 마찬가지로 IDH1 억제제인 이보시데닙은 IDH1 돌연변이 담관암 환자에서 효과를 입증했습니다. 면역요법, 특히 펨브롤리주맙과 같은 체크포인트 억제제도 검토되고 있지만, 담관암의 반응률은 다른 암에 비해 낮습니다. 현재 진행 중인 임상시험에서는 이러한 치료법의 효과를 높이고 내성 메커니즘을 극복하기 위한 병용 요법을 연구하고 있습니다.

담관암 치료제 시장의 성장은 몇 가지 요인에 의해 이루어지고 있습니다. 담관암 발병률 증가는 B형 및 C형 간염과 같은 간 질환 및 감염성 질환 증가로 인해 치료가 필요한 환자층이 확대되고 있습니다. 유전체 프로파일링과 맞춤의료의 기술적 발전은 치료 가능한 돌연변이 식별을 용이하게 하여 표적치료제의 개발과 채택을 촉진하고 있습니다. 또한, 제약회사들의 연구개발에 대한 막대한 투자는 새로운 치료제의 강력한 파이프라인으로 이어지고 있습니다. 또한, 희귀질환 치료제에 대한 규제 당국의 지원과 신속한 승인 절차도 시장 성장을 가속하고 있습니다. 또한, 표적 치료와 병용 요법의 가능성에 대한 의료 전문가와 환자들의 인식이 높아지면서 수요를 촉진하고 있습니다. 이러한 추세에 따라 담관암 치료제 시장은 기술 발전, 암 생물학에 대한 깊은 이해, 혁신적인 치료 전략에 대한 관심이 높아짐에 따라 크게 성장할 수 있는 여건을 갖추고 있습니다.

조사 대상 기업 예시(총 86건)

  • Bold Therapeutics
  • CStone Pharmaceuticals
  • Genfit SA
  • J-Pharma Co.
  • Lisata Therapeutics
  • Owkin, Inc.
  • RedHill Biopharma Ltd.
  • RenovoRx, Inc.
  • Servier Laboratories
  • Specialised Therapeutics Australia Pty Limited
  • Taiho Pharmaceutical Co.
  • Tempest Therapeutics
  • TriSalus Life Sciences
  • Tyra Biosciences;
  • Tyra Biosciences

    목차

    제1장 조사 방법

    제2장 주요 요약

    • 시장 개요
    • 주요 기업
    • 시장 동향과 촉진요인
    • 세계 시장 전망

    제3장 시장 분석

    • 미국
    • 캐나다
    • 일본
    • 중국
    • 유럽
    • 프랑스
    • 독일
    • 이탈리아
    • 영국
    • 기타 유럽
    • 아시아태평양
    • 기타 지역

    제4장 경쟁

    LSH 24.09.05

    Global Cholangiocarcinoma Therapeutics Market to Reach US$962.0 Million by 2030

    The global market for Cholangiocarcinoma Therapeutics estimated at US$863.8 Million in the year 2023, is expected to reach US$962.0 Million by 2030, growing at a CAGR of 1.6% over the analysis period 2023-2030. Targeted Therapy, one of the segments analyzed in the report, is expected to record a 2.0% CAGR and reach US$592.5 Million by the end of the analysis period. Growth in the Chemotherapy segment is estimated at 0.8% CAGR over the analysis period.

    The U.S. Market is Estimated at US$227.1 Million While China is Forecast to Grow at 1.3% CAGR

    The Cholangiocarcinoma Therapeutics market in the U.S. is estimated at US$227.1 Million in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$153.2 Million by the year 2030 trailing a CAGR of 1.3% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.2% and 1.3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 0.5% CAGR.

    Global Cholangiocarcinoma Therapeutics Market - Key Trends and Drivers Summarized

    Cholangiocarcinoma, also known as bile duct cancer, is a rare but aggressive form of cancer originating in the bile ducts. The disease is often diagnosed at an advanced stage due to its asymptomatic nature in the early phases, which complicates treatment and worsens prognosis. Standard treatment options for cholangiocarcinoma include surgery, chemotherapy, and radiation therapy. Surgery, particularly resection, offers the best chance for a cure, but it is only feasible in a minority of patients due to the late presentation of the disease. For unresectable or metastatic cases, chemotherapy regimens typically include combinations such as gemcitabine with cisplatin, although these treatments primarily aim to prolong survival rather than cure the disease. Recently, the advent of targeted therapies and immunotherapies has provided new avenues for treatment, giving hope to patients with advanced cholangiocarcinoma.

    The landscape of cholangiocarcinoma therapeutics has been significantly transformed by advances in molecular biology and genetics, leading to the development of targeted therapies. These therapies are designed to attack specific genetic mutations or alterations that drive cancer growth. For instance, FGFR2 (fibroblast growth factor receptor 2) fusions and IDH1 (isocitrate dehydrogenase 1) mutations are found in a subset of cholangiocarcinoma patients and have become targets for novel drugs. Pemigatinib and infigratinib, both FGFR inhibitors, have shown efficacy in clinical trials, offering new treatment options for patients with FGFR2 fusions. Similarly, ivosidenib, an IDH1 inhibitor, has demonstrated benefits for patients with IDH1-mutant cholangiocarcinoma. Immunotherapy, particularly checkpoint inhibitors like pembrolizumab, is also being explored, although the response rates in cholangiocarcinoma have been modest compared to other cancers. Ongoing clinical trials are investigating combinations of these therapies to enhance their effectiveness and overcome resistance mechanisms.

    The growth in the cholangiocarcinoma therapeutics market is driven by several factors. The increasing incidence of cholangiocarcinoma, partly attributed to rising rates of liver diseases and infections such as hepatitis B and C, is expanding the patient population in need of treatment. Technological advancements in genomic profiling and personalized medicine are facilitating the identification of actionable mutations, thereby driving the development and adoption of targeted therapies. Furthermore, substantial investment in research and development by pharmaceutical companies is leading to a robust pipeline of novel therapeutics. Regulatory support and expedited approval processes for orphan drugs are also propelling market growth, as these incentives encourage the development of treatments for rare diseases like cholangiocarcinoma. Additionally growing awareness among healthcare professionals and patients about the potential of targeted and combination therapies is boosting demand. As these trends continue to evolve, the cholangiocarcinoma therapeutics market is poised for significant expansion, driven by technological advancements, a deeper understanding of cancer biology, and a strong focus on innovative treatment strategies.

    Select Competitors (Total 86 Featured) -

    • Bold Therapeutics
    • CStone Pharmaceuticals
    • Genfit SA
    • J-Pharma Co., Ltd.
    • Lisata Therapeutics
    • Owkin, Inc.
    • RedHill Biopharma Ltd.
    • RenovoRx, Inc.
    • Servier Laboratories
    • Specialised Therapeutics Australia Pty Limited
    • Taiho Pharmaceutical Co., Ltd.
    • Tempest Therapeutics
    • TriSalus Life Sciences
    • Tyra Biosciences;

    TABLE OF CONTENTS

    I. METHODOLOGY

    II. EXECUTIVE SUMMARY

    • 1. MARKET OVERVIEW
      • Influencer Market Insights
      • Global Economic Update
      • Cholangiocarcinoma Therapeutics - Global Key Competitors Percentage Market Share in 2024 (E)
      • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
    • 2. FOCUS ON SELECT PLAYERS
    • 3. MARKET TRENDS & DRIVERS
      • Increasing Incidence of Cholangiocarcinoma Expands Addressable Market Opportunity
      • Advances in Genomic Profiling Propel Development of Targeted Therapies
      • Rising Rates of Liver Diseases and Hepatitis Infections Drive Demand for Treatments
      • Technological Innovations in Personalized Medicine Strengthen Business Case for Novel Therapies
      • Growing Awareness of Targeted and Combination Therapies Accelerates Market Adoption
      • Identification of Actionable Genetic Mutations Throws Spotlight on Precision Medicine
      • Increasing Use of FGFR and IDH1 Inhibitors Drives Market Expansion
      • Exploration of Immunotherapy Combinations Generates New Opportunities
      • Challenges in Early Diagnosis and Late-Stage Presentation Propel Need for Advanced Therapeutics
      • Integration of Biomarker Testing in Treatment Planning Enhances Efficacy
      • Rising Healthcare Expenditure Expands Reach of Therapies
      • Focus on Overcoming Resistance Mechanisms Sustains Growth in Therapeutic Development
      • Adoption of Precision Oncology Approaches Drives Development of Personalized Therapies
    • 4. GLOBAL MARKET PERSPECTIVE
      • TABLE 1: World Cholangiocarcinoma Therapeutics Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
      • TABLE 2: World Recent Past, Current & Future Analysis for Cholangiocarcinoma Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
      • TABLE 3: World Historic Review for Cholangiocarcinoma Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
      • TABLE 4: World 16-Year Perspective for Cholangiocarcinoma Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2014, 2024 & 2030
      • TABLE 5: World Recent Past, Current & Future Analysis for Targeted Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
      • TABLE 6: World Historic Review for Targeted Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
      • TABLE 7: World 16-Year Perspective for Targeted Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
      • TABLE 8: World Recent Past, Current & Future Analysis for Chemotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
      • TABLE 9: World Historic Review for Chemotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
      • TABLE 10: World 16-Year Perspective for Chemotherapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
      • TABLE 11: World Recent Past, Current & Future Analysis for Immunotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
      • TABLE 12: World Historic Review for Immunotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
      • TABLE 13: World 16-Year Perspective for Immunotherapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
      • TABLE 14: World Recent Past, Current & Future Analysis for Other Therapies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
      • TABLE 15: World Historic Review for Other Therapies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
      • TABLE 16: World 16-Year Perspective for Other Therapies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
      • TABLE 17: World Recent Past, Current & Future Analysis for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
      • TABLE 18: World Historic Review for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
      • TABLE 19: World 16-Year Perspective for Hospital Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
      • TABLE 20: World Recent Past, Current & Future Analysis for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
      • TABLE 21: World Historic Review for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
      • TABLE 22: World 16-Year Perspective for Retail Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
      • TABLE 23: World Recent Past, Current & Future Analysis for Online Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
      • TABLE 24: World Historic Review for Online Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
      • TABLE 25: World 16-Year Perspective for Online Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030

    III. MARKET ANALYSIS

    • UNITED STATES
      • Cholangiocarcinoma Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
      • TABLE 26: USA Recent Past, Current & Future Analysis for Cholangiocarcinoma Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Immunotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
      • TABLE 27: USA Historic Review for Cholangiocarcinoma Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Immunotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
      • TABLE 28: USA 16-Year Perspective for Cholangiocarcinoma Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Chemotherapy, Immunotherapy and Other Therapies for the Years 2014, 2024 & 2030
      • TABLE 29: USA Recent Past, Current & Future Analysis for Cholangiocarcinoma Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
      • TABLE 30: USA Historic Review for Cholangiocarcinoma Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
      • TABLE 31: USA 16-Year Perspective for Cholangiocarcinoma Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
    • CANADA
      • TABLE 32: Canada Recent Past, Current & Future Analysis for Cholangiocarcinoma Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Immunotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
      • TABLE 33: Canada Historic Review for Cholangiocarcinoma Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Immunotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
      • TABLE 34: Canada 16-Year Perspective for Cholangiocarcinoma Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Chemotherapy, Immunotherapy and Other Therapies for the Years 2014, 2024 & 2030
      • TABLE 35: Canada Recent Past, Current & Future Analysis for Cholangiocarcinoma Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
      • TABLE 36: Canada Historic Review for Cholangiocarcinoma Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
      • TABLE 37: Canada 16-Year Perspective for Cholangiocarcinoma Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
    • JAPAN
      • Cholangiocarcinoma Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
      • TABLE 38: Japan Recent Past, Current & Future Analysis for Cholangiocarcinoma Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Immunotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
      • TABLE 39: Japan Historic Review for Cholangiocarcinoma Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Immunotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
      • TABLE 40: Japan 16-Year Perspective for Cholangiocarcinoma Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Chemotherapy, Immunotherapy and Other Therapies for the Years 2014, 2024 & 2030
      • TABLE 41: Japan Recent Past, Current & Future Analysis for Cholangiocarcinoma Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
      • TABLE 42: Japan Historic Review for Cholangiocarcinoma Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
      • TABLE 43: Japan 16-Year Perspective for Cholangiocarcinoma Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
    • CHINA
      • Cholangiocarcinoma Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
      • TABLE 44: China Recent Past, Current & Future Analysis for Cholangiocarcinoma Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Immunotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
      • TABLE 45: China Historic Review for Cholangiocarcinoma Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Immunotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
      • TABLE 46: China 16-Year Perspective for Cholangiocarcinoma Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Chemotherapy, Immunotherapy and Other Therapies for the Years 2014, 2024 & 2030
      • TABLE 47: China Recent Past, Current & Future Analysis for Cholangiocarcinoma Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
      • TABLE 48: China Historic Review for Cholangiocarcinoma Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
      • TABLE 49: China 16-Year Perspective for Cholangiocarcinoma Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
    • EUROPE
      • Cholangiocarcinoma Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
      • TABLE 50: Europe Recent Past, Current & Future Analysis for Cholangiocarcinoma Therapeutics by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
      • TABLE 51: Europe Historic Review for Cholangiocarcinoma Therapeutics by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
      • TABLE 52: Europe 16-Year Perspective for Cholangiocarcinoma Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2014, 2024 & 2030
      • TABLE 53: Europe Recent Past, Current & Future Analysis for Cholangiocarcinoma Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Immunotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
      • TABLE 54: Europe Historic Review for Cholangiocarcinoma Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Immunotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
      • TABLE 55: Europe 16-Year Perspective for Cholangiocarcinoma Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Chemotherapy, Immunotherapy and Other Therapies for the Years 2014, 2024 & 2030
      • TABLE 56: Europe Recent Past, Current & Future Analysis for Cholangiocarcinoma Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
      • TABLE 57: Europe Historic Review for Cholangiocarcinoma Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
      • TABLE 58: Europe 16-Year Perspective for Cholangiocarcinoma Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
    • FRANCE
      • Cholangiocarcinoma Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
      • TABLE 59: France Recent Past, Current & Future Analysis for Cholangiocarcinoma Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Immunotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
      • TABLE 60: France Historic Review for Cholangiocarcinoma Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Immunotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
      • TABLE 61: France 16-Year Perspective for Cholangiocarcinoma Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Chemotherapy, Immunotherapy and Other Therapies for the Years 2014, 2024 & 2030
      • TABLE 62: France Recent Past, Current & Future Analysis for Cholangiocarcinoma Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
      • TABLE 63: France Historic Review for Cholangiocarcinoma Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
      • TABLE 64: France 16-Year Perspective for Cholangiocarcinoma Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
    • GERMANY
      • Cholangiocarcinoma Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
      • TABLE 65: Germany Recent Past, Current & Future Analysis for Cholangiocarcinoma Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Immunotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
      • TABLE 66: Germany Historic Review for Cholangiocarcinoma Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Immunotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
      • TABLE 67: Germany 16-Year Perspective for Cholangiocarcinoma Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Chemotherapy, Immunotherapy and Other Therapies for the Years 2014, 2024 & 2030
      • TABLE 68: Germany Recent Past, Current & Future Analysis for Cholangiocarcinoma Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
      • TABLE 69: Germany Historic Review for Cholangiocarcinoma Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
      • TABLE 70: Germany 16-Year Perspective for Cholangiocarcinoma Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
    • ITALY
      • TABLE 71: Italy Recent Past, Current & Future Analysis for Cholangiocarcinoma Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Immunotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
      • TABLE 72: Italy Historic Review for Cholangiocarcinoma Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Immunotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
      • TABLE 73: Italy 16-Year Perspective for Cholangiocarcinoma Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Chemotherapy, Immunotherapy and Other Therapies for the Years 2014, 2024 & 2030
      • TABLE 74: Italy Recent Past, Current & Future Analysis for Cholangiocarcinoma Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
      • TABLE 75: Italy Historic Review for Cholangiocarcinoma Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
      • TABLE 76: Italy 16-Year Perspective for Cholangiocarcinoma Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
    • UNITED KINGDOM
      • Cholangiocarcinoma Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
      • TABLE 77: UK Recent Past, Current & Future Analysis for Cholangiocarcinoma Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Immunotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
      • TABLE 78: UK Historic Review for Cholangiocarcinoma Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Immunotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
      • TABLE 79: UK 16-Year Perspective for Cholangiocarcinoma Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Chemotherapy, Immunotherapy and Other Therapies for the Years 2014, 2024 & 2030
      • TABLE 80: UK Recent Past, Current & Future Analysis for Cholangiocarcinoma Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
      • TABLE 81: UK Historic Review for Cholangiocarcinoma Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
      • TABLE 82: UK 16-Year Perspective for Cholangiocarcinoma Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
    • REST OF EUROPE
      • TABLE 83: Rest of Europe Recent Past, Current & Future Analysis for Cholangiocarcinoma Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Immunotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
      • TABLE 84: Rest of Europe Historic Review for Cholangiocarcinoma Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Immunotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
      • TABLE 85: Rest of Europe 16-Year Perspective for Cholangiocarcinoma Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Chemotherapy, Immunotherapy and Other Therapies for the Years 2014, 2024 & 2030
      • TABLE 86: Rest of Europe Recent Past, Current & Future Analysis for Cholangiocarcinoma Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
      • TABLE 87: Rest of Europe Historic Review for Cholangiocarcinoma Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
      • TABLE 88: Rest of Europe 16-Year Perspective for Cholangiocarcinoma Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
    • ASIA-PACIFIC
      • Cholangiocarcinoma Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
      • TABLE 89: Asia-Pacific Recent Past, Current & Future Analysis for Cholangiocarcinoma Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Immunotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
      • TABLE 90: Asia-Pacific Historic Review for Cholangiocarcinoma Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Immunotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
      • TABLE 91: Asia-Pacific 16-Year Perspective for Cholangiocarcinoma Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Chemotherapy, Immunotherapy and Other Therapies for the Years 2014, 2024 & 2030
      • TABLE 92: Asia-Pacific Recent Past, Current & Future Analysis for Cholangiocarcinoma Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
      • TABLE 93: Asia-Pacific Historic Review for Cholangiocarcinoma Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
      • TABLE 94: Asia-Pacific 16-Year Perspective for Cholangiocarcinoma Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
    • REST OF WORLD
      • TABLE 95: Rest of World Recent Past, Current & Future Analysis for Cholangiocarcinoma Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Immunotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
      • TABLE 96: Rest of World Historic Review for Cholangiocarcinoma Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Immunotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
      • TABLE 97: Rest of World 16-Year Perspective for Cholangiocarcinoma Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Chemotherapy, Immunotherapy and Other Therapies for the Years 2014, 2024 & 2030
      • TABLE 98: Rest of World Recent Past, Current & Future Analysis for Cholangiocarcinoma Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
      • TABLE 99: Rest of World Historic Review for Cholangiocarcinoma Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
      • TABLE 100: Rest of World 16-Year Perspective for Cholangiocarcinoma Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030

    IV. COMPETITION

    • 샘플 요청 목록
    0 건의 상품을 선택 중
    목록 보기
    전체삭제